BRAF and non-small cell lung carcinoma: The latter combination of dabrafenib plus trametinib has also recently been approved for the treatment of BRAF-mutated non-small cell lung cancer (NSCLC) [32] and for the treatment of BRAF-mutated anaplastic thyroid carcinoma [33].